Status:

RECRUITING

Atrial Fibrosis in Obstructive Sleep Apnea Patients: A Pilot Study

Lead Sponsor:

Tulane University

Conditions:

Atrial Fibrillation

Obstructive Sleep Apnea

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

The investigators hypothesize that Obstructive Sleep Apnea (OSA) is an independent risk factor for atrial fibrosis development. The investigators aim to prove the presence of atrial fibrosis on Delaye...

Detailed Description

This is a cross sectional pilot study. Sixty mild to severe OSA patients and five age- and Body Mass Index (BMI)-matched controls will undergo a DE-MRI. Demographics, medical history and polysomnograp...

Eligibility Criteria

Inclusion

  • Group A: 10 patients 18-75-year-old With mild OSA (5\<AHI\<15), confirmed by polysomnography. No previous AF diagnosis on the medical chart
  • Group B: 10 patients 18-75-year-old With moderate OSA (15\<AHI\<30), confirmed by polysomnography. No previous AF diagnosis on the medical chart
  • Group C: 10 patients 18-75-year-old With severe OSA (AHI\>30), confirmed by polysomnography. No previous AF diagnosis on the medical chart
  • Group D (mild OSA+ AF): 10 patients 18-75-year-old With mild OSA (5\<AHI\<15), confirmed by polysomnography. Previous AF diagnosis
  • In this group, patients with AF and OSA who already have done MRI might be included.
  • Group E (severe OSA +AF): 10 patients 18-75-year-old With severe OSA (AHI\>30), confirmed by polysomnography. Previous AF diagnosis
  • \*In this group, patients with AF and OSA who already have done MRI might be included.
  • Group F (Control): 10 Patients 18-75-year-old No previous OSA and/or AF Diagnosis on the medical chart

Exclusion

  • History of chronic heart failure (LVEF \< 50%), AF, myocardial infarction, valvular disease.
  • Prior cardiac or chest surgery.
  • Other advanced pulmonary disease (severe Chronic Obstructive Pulmonary Disease (COPD) or asthma, pulmonary hypertension) or central sleep apnea.
  • Contraindications to DE-MRI (e.g. allergy to gadolinium, pacemakers, defibrillators (ICD's), other devices/implants contraindicated for MRI, glomerular filtration rate \<30 ml/min, etc.).
  • Pregnancy.
  • Inability to give informed consent.

Key Trial Info

Start Date :

July 12 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2025

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT04814420

Start Date

July 12 2021

End Date

December 1 2025

Last Update

January 28 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

East Jefferson General Hospital

New Orleans, Louisiana, United States, 70006

2

Tulane University Medical Center

New Orleans, Louisiana, United States, 70112